Xencor (NASDAQ:XNCR) Sets New 1-Year Low – Here’s Why

Xencor, Inc. (NASDAQ:XNCR) shares hit a new 52-week low on Tuesday . The company traded as low as $13.91 and last traded at $14.12, with a volume of 23914 shares traded. The stock had previously closed at $14.46.

Analysts Set New Price Targets

A number of brokerages recently weighed in on XNCR. Wells Fargo & Company lowered their target price on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a report on Friday. Wedbush restated an “outperform” rating and set a $38.00 target price on shares of Xencor in a report on Thursday, November 7th. BMO Capital Markets reiterated an “outperform” rating and issued a $34.00 price objective (up from $32.00) on shares of Xencor in a report on Friday, November 8th. Piper Sandler upgraded shares of Xencor from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $20.00 to $30.00 in a report on Monday, December 2nd. Finally, StockNews.com downgraded shares of Xencor from a “hold” rating to a “sell” rating in a report on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $34.38.

Xencor Price Performance

The stock has a market capitalization of $976.67 million, a price-to-earnings ratio of -4.39 and a beta of 0.70. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The business’s 50 day simple moving average is $19.23 and its 200-day simple moving average is $20.69.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. The firm had revenue of $52.79 million for the quarter, compared to the consensus estimate of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. On average, research analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Alan Bruce Montgomery sold 1,421 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $27.03, for a total value of $38,409.63. Following the sale, the director now directly owns 9,140 shares in the company, valued at approximately $247,054.20. This trade represents a 13.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 5.23% of the company’s stock.

Institutional Investors Weigh In On Xencor

A number of hedge funds have recently made changes to their positions in XNCR. Sterling Capital Management LLC boosted its stake in shares of Xencor by 732.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,040 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Xencor in the 4th quarter valued at approximately $34,000. GAMMA Investing LLC boosted its stake in shares of Xencor by 31.0% in the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 508 shares in the last quarter. KBC Group NV boosted its stake in shares of Xencor by 63.5% in the 3rd quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 1,213 shares in the last quarter. Finally, Quarry LP boosted its position in Xencor by 111.4% during the 3rd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock worth $80,000 after buying an additional 2,108 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.